Last reviewed · How we verify

MV140 — Competitive Intelligence Brief

MV140 (MV140) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial lysate vaccine. Area: Immunology / Infectious Disease.

phase 3 Bacterial lysate vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MV140 (MV140) — Inmunotek S.L.. MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MV140 TARGET MV140 Inmunotek S.L. phase 3 Bacterial lysate vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial lysate vaccine class)

  1. Inmunotek S.L. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MV140 — Competitive Intelligence Brief. https://druglandscape.com/ci/mv140. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: